Quick-Med Technologies to Present NIMBUS at the Symposium on Advanced Wound Care and Wound Healing Society Meeting

Quick-Med Technologies, Inc. (OTCBB:QMDT) an emerging life sciences company specializing in novel antimicrobial technologies, announced that data on three of its proprietary antimicrobial technologies is being presented at the 2009 Symposium on Advanced Wound Care and the Wound Healing Society meeting. This event is the premier annual meeting of physicians, researchers and other wound care specialists and is being held in Dallas, Texas, on April 26-29, 2009. Quick-Med’s scientists will present four abstracts at the prestigious meeting.

Two of Quick-Med’s abstracts feature key aspects of the company’s NIMBUS^® Barrier Gauze Dressing, a unique, non-leaching antimicrobial technology that recently received FDA clearance:

Antimicrobial Wound Dressings: Mechanisms and Function – A profile of the barrier properties of NIMBUS that substantiates its performance in the presence of wound exudate while permitting safe and rapid healing without risk of bacterial mutation. It is a predicate material ready for incorporation into other application formats.

Bacterial Resistance Issues in Wound Care and Wound Dressings – A review of the basic process that leads to the development of bacterial resistance by various microbicidal materials and a summary of the test results demonstrating that NIMBUS does not display this mutation effect.

NIMBUS offers improved safety and efficacy. It is unique in that it is a sterile bacterial barrier that prohibits the transfer of microorganisms into the wound because the microbicidal agent is irreversibly bound to the dressing. "NIMBUS is the first bound, antimicrobial material – rather than delivering an antimicrobial into the wound, it creates a barrier that won’t allow bacteria to penetrate the dressing or grow in the wound fluid,” says Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and Past President of the Wound Healing Society. "Traditional wound dressings absorb fluid from the wound and act as a great incubator for bacteria that are shed back into the wound.”

NIMBUS is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Product labeling has been allowed that indicates various organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are killed at levels exceeding 99.999%. NIMBUS barrier gauze will be available in June under license from Quick-Med and will be marketed as BIOGUARD™ by Derma Sciences.

Additional Technologies

Additionally, Quick-Med posters will present data on NimbuDerm™, the company’s persistent hand sanitizer technology, and Stay Fresh™, a new highly durable textiles technology that is especially well suited for health care applications:

Hand Sanitizer Technology and Progress Toward a more Functional Concept – Achievement of sustained antimicrobial protection exceeding six hours via the development of a high performance, breathable skin sanitizer coating which is a barrier to adventitious contamination.

Medical Textile Fabric as a Barrier to Pathogen Transmission – A profile of the high performance, high durability properties of Quick-Med’s Stay Fresh™ textiles technology. This novel antimicrobial treatment achieves 99.999% kill performance against both Gram-positive and Gram-negative bacteria that is sustained through more than 50 laundering cycles, outperforming available antimicrobial treatments for healthcare uniforms and scrubs, patient bed linens, and other medical textile fabric applications.

About the Symposium on Advanced Wound Care/Wound Healing Society Meeting

The 22^nd Annual SAWC/WHS Meeting is the premier educational wound care program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend.

About NIMBUS

NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material into the wound and impeding the wound healing process. It is a novel antimicrobial technology: bonded and effective even in high concentrations of body fluids.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. (OTCBB:QMDT) is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats while advancing its Stay Fresh and NimbuDerm technology platforms. Additionally, the Company’s MultiStat^® compounds have been shown to be 1,000 times more potent than the natural matrix metalloproteinase inhibitors that are present in human blood and some plant extracts. For more information, see: www.quickmedtech.com.

© 2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS^® and MultiStat^® are registered trademarks and NimbuDerm™ and Stay Fresh™ are trademarks of Quick-Med Technologies, Inc. BIOGUARD™ is a trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.